Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. Independent Director's 2025 Annual Performance Report
To all shareholders and shareholder representatives:
As an incumbent independent director of Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. (hereinafter referred to as "Asia-Pacific Pharmaceutical" or "the Company") for the year 2025, I have strictly adhered to the provisions and requirements of relevant laws and regulations, including the "Company Law," "Securities Law," "Administrative Measures for Independent Directors of Listed Companies," "Shenzhen Stock Exchange Listed Company Self-Regulatory Management Guide No. 1—Normative Operation of Main Board Listed Companies," and the "Articles of Association" and "Independent Director Work System." I have diligently fulfilled my duties as an independent director, actively attended relevant meetings, listened to reports on the company's production and operation, paid attention to financial status and corporate governance, ensured the independence of my duties, and effectively protected the legitimate rights and interests of the company and all shareholders, especially minority shareholders. Here is my performance report for 2025:
I. Basic Information of the Independent Director
Cai Min, born in September 1986, is a Chinese national with a master's degree and is a practicing lawyer. She has served as a member of the project review committee for a large listed city commercial bank (wholly-owned subsidiary) and a listed rural commercial bank, a legal and compliance manager, and has long focused on corporate investment and financing, mergers and acquisitions, restructuring, private equity and financial product innovation, equity structure design, and corporate governance. She has provided legal services to many large state-owned enterprises, financial institutions, and other public institutions. She is currently a senior partner and deputy director of the Securities Affairs Department at Zhejiang Dianjin Law Firm. She has served as an independent director of Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. from April 2022 to February 2026.